Skip to content
Talk to us
Talk to us

Monitoring report · published · reflects the rules at that date

SCCS published final Opinion on Prostaglandin Analogues  

Our monitoring reports record the changes to cosmetics rules in a given period, and we publish one each month. Each one is a dated publication: it reflects the rules on the date it was published and is not updated afterwards. For what applies today, read the latest briefings or ask us.

See what happens after launch

What’s new?

On the 2nd of February 2026, the Scientific Committee on Consumer Safety (SCCS) adopted its final opinion on the safety of three Prostagladin Analogues: Methylamido-Dihydro-Noralfaprostal (MDN), Isopropyl Cloprostenate (IPCP) and Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE), ingredients intended to be used to promote the growth of eyelashes and eyebrows. The preliminary opinion was open for comments until August 18, 2025, and considering the information received during the commenting period, the SCCS released its final opinion with a slight rewording in the final conclusions.  

This assessment was requested due to ongoing industry efforts to demonstrate the safety of Prostaglandin Analogues following the German Federal Institute for Risk Assessment (BfR) alert in 2018, which highlighted health risks associated with eyelash growth treatments containing these substances. Based on potent pharmacological activity and the lack of data excluding potential reprotoxicity, the SCCS concluded that these ingredients are not safe for use.  

What now?

The European Commission will likely amend Annex II of the Cosmetics Regulation to include these ingredients, with typical transition periods of 18-24 months for compliance. 

References:

SCCS (Scientific Committee on Consumer Safety), Opinion on prostaglandin analogues used in cosmetic products, preliminary version of 28 May 2025, final version of 2 February, SCCS/1680/25

Need to know what this means for a product you have on the market now?

Ask the team for this area

One question works best. Leave out confidential product details; we can take those up by email.

Our team replies to every question. The reply goes to the email you gave.

We use your email to answer this question and for nothing else. Privacy and cookies

Follow an area

One email when an area publishes, in the language you choose. Nothing else.

Talk to us

Tell us the product, the market and the date you are working to. If the date is not realistic, we will say so.

Talk about a product Request a proposal
Need a standing regulatory partner? See ongoing support →